^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Cecolin (recombinant human papillomavirus bivalent (types 16, 18) vaccine (Escherichia coli))

Associations
Trials
Company:
Wantai BioPharm
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
7ms
Immunogenicity and Safety of One Dose of HPV Vaccine (clinicaltrials.gov)
P4, N=200, Completed, Xiamen Innovax Biotech Co., Ltd
New P4 trial
|
Cecolin (recombinant human papillomavirus bivalent (types 16, 18) vaccine (Escherichia coli)) • Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine)
10ms
Phase 3 Trial of a Bivalent HPV Vaccine (Cecolin®) in Young Girls (clinicaltrials.gov)
P3, N=1025, Completed, PATH | Active, not recruiting --> Completed
Trial completion
|
Cecolin (recombinant human papillomavirus bivalent (types 16, 18) vaccine (Escherichia coli)) • Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine)
over1year
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial. (PubMed, Lancet Infect Dis)
Cecolin 9 induced non-inferior HPV type-specific immune responses compared with Gardasil 9 and is a potential candidate to accelerate the elimination of cervical cancer by allowing for global accessibility to 9-valent HPV vaccinations, especially in low-income and middle-income countries.
Journal • Head-to-Head
|
Cecolin (recombinant human papillomavirus bivalent (types 16, 18) vaccine (Escherichia coli)) • Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
over1year
Impact and Cost-Effectiveness of Alternative Human Papillomavirus Vaccines for Preadolescent Girls in Mozambique: A Modelling Study. (PubMed, Vaccines (Basel))
This study evaluated the health and economic impact of the current HPV vaccine (GARDASIL hereafter referred to as GARDASIL-4) and two other vaccines (CECOLIN and CERVARIX) that could be used in the future. At a willingness-to-pay (WTP) threshold set at 35% of Gross Domestic Product (GDP) per capita, HPV vaccination is cost-effective in Mozambique. The optimal vaccine choice depends on cross-protection assumptions.
Journal • HEOR • Cost-effectiveness • Cost effectiveness
|
Cecolin (recombinant human papillomavirus bivalent (types 16, 18) vaccine (Escherichia coli)) • Cervarix (recombinant human papillomavirus bivalent vaccine) • Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine)
over1year
Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study. (PubMed, Vaccine)
HPV vaccination for girls is highly cost-effective in Kenya. Compared to GARDASIL-4, alternative products could provide similar or greater health benefits at lower net costs. Substantial government funding will be required to reach and sustain coverage targets as Kenya graduates from Gavi support. A single dose strategy is likely to have similar benefits for less cost.
Journal • HEOR • Cost-effectiveness • Cost effectiveness
|
Cecolin (recombinant human papillomavirus bivalent (types 16, 18) vaccine (Escherichia coli)) • Cervarix (recombinant human papillomavirus bivalent vaccine) • Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)